The Effect of a Herbal Product Containing Vernonia Amygdalina L. (Asteraceae) and Hibiscus Sabdariffa L. (Malvaceae) on Glycemic Index in Sub-Acute Dexamethasone Treated Mice.

This study focused on evaluating the potentials of two variants of water soluble polyherbal nutraceutical products containing Vernonia amygdalina (Bitter leaf) and Hibiscus sabdariffa (Zobo calyces) in mitigating the toxicity due to dexamethasone a widely used synthetic corticosteroid associated with adverse effects, including hyperglycemia, and oxidative stress among others. The two polyherbal products variants: POWSG-D-(10% w/w bitter leaf decoction and 10% w/w Zobo decoction extract), and POWSG-C-10% w/w bitter leaf cold maceration extract and 10% w/w Zobo decoction extract) were used in this study. Phytochemical analysis and physico-chemical parameters (residue on drying, total ash and loss on drying) were done following standard methods as recommended by the World Health Organization (WHO) for herbal product.
In vitro antioxidant assay was done using the DPPH (2,2-diphenyl-1-picrylhydrazyl) spectrophotometric method. Effect on glycemic index (fasting blood sugar) was done in vivo in sub-acute dexamethasone treated mice. phytochemical analyses confirmed the presence of phenolics with the UV-Visible spectra showing corroborating characteristic absorption peaks at 198-202 nm and 273–275 nm, evidence for phenolics. Quality assessments demonstrated good granule flow properties, with cold maceration granules exhibiting superior compressibility. Antioxidant activity was moderate, with IC50 values of 500 µg/mL and 800 µg/mL for POWSG-C and POWSG-D respectively, compared to Vitamin C (IC50: 9 µg/mL). From the result of the bioassay, the high dose (800 mg/kg body weight) decoction successfully mitigated hyperglycemia on the sub-acute dexamethasone induced mice with 1.75mMol/L and 1.80mMol/L on day 18 and 25 respectively compared to the other group of animals. These findings highlight the potential of this polyherbal formulation as a cost-effective, accessible nutraceutical for the treatment of hyperglycemia especially for immuno-compromised subjects undergoing corticosteroid regimen, and for general health and wellbeing with further optimization recommended to enhance efficacy and antioxidant activity.

Standardization, Hibiscus sabdariffa, Vernonia amygdalina, Polyherbal granules dosage form, Corticosteroid hyperglycemia.

1. Poludasari, S. K., & Sridevi, C. (2022). A Case Report on Multiple Adverse Events Associated with Systemic Usage of Dexamethasone. Journal of Drug Delivery and Therapeutics, 12(6), I-III. [Google Scholar] [Crossref]

2. American College of Rheumatology. (2022). American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis and Rheumatology, 74(8), 1235-1256. [Google Scholar] [Crossref]

3. Sutherland, C., Waltner-Law, M., Gnudi, L., Kahn, B. B., & Granner, D. K. (1998). Activation of the ras mitogen-activated protein kinase-ribosomal protein kinase pathway is not required for the repression of phosphoenolpyruvate carboxykinase gene transcription by insulin. The Journal of biological chemistry, 273(6), 3198–3204. [Google Scholar] [Crossref]

4. Shah, P., Kalra, S., Yadav, Y., Deka, N., Lathia, T., Jacob, J. J., Kota, S. K., Bhattacharya, S., Gadve, S. S., Subramanium, K. A. V., George, J., Iyer, V., Chandratreya, S., Aggrawal, P. K., Singh, S. K., Joshi, A., Selvan, C., Priya, G., Dhingra, A., & Das, S. (2022). Management of glucocorticoid-induced hyperglycemia. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 15, 1751–1766. [Google Scholar] [Crossref]

5. Weinstein R. S. (2012). Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinology and metabolism clinics of North America, 41(3), 595–611. [Google Scholar] [Crossref]

6. Perry, J., Lutz, L., and Peterson, C. (2021). Neuropsychiatric effects of glucocorticoids. Psychiatric Clinics of North America, 44(3), 463-474. [Google Scholar] [Crossref]

7. Patel, D. K., Kumar, R., & Prasad, S. K. (2011). Antidiabetic and in vitro antioxidant potential of Hybanthus enneaspermus (Linn) F. Muell in streptozotocin–induced diabetic rats. Asian Pacific Journal of Tropical Biomedicine, 1(4), 316–322. [Google Scholar] [Crossref]

8. Gbolade, A. A. (2009). Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria. Journal of Ethnopharmacology, 121(1), 35–139. [Google Scholar] [Crossref]

9. WAHP (2013). West African Herbal Pharmacopoeia. A publication of the West African Health Organisation (WAHO), Bobo-Dioulasso, Burkina Faso. [Google Scholar] [Crossref]

10. Ijeh, I. I., & Ejike, C. E. C. C. (2011). Current perspectives on the medicinal potentials of Vernonia amygdalina Del. Journal of Medicinal Plants Research, 5(7), 1051–1061. [Google Scholar] [Crossref]

11. Yeola, B. S., Pisal, S. S., Paradkar, A. R., and Mahadik, K. R. (2000). New drug delivery systems for the elderly. Indian Drugs, 7, 312-318. [Google Scholar] [Crossref]

12. Ghosh, T., Ghosh, A., and Prasad, D. (2011). A review on new generation orodispersible tablets and its future prospective. International Journal of Pharmacy and Pharmaceutical Sciences, 3(1), 1-7. [Google Scholar] [Crossref]

13. Redkar, M., Gore, S., and Devrajan, P. (2002). D-zolv taste-masked mouth dissolving tablet. Indian Journal of Pharmaceutical Sciences, 3, 291-292. [Google Scholar] [Crossref]

14. Bhowmik, D., Chiranjib, B., and Pankaj. (2009). Fast dissolving tablet: An overview. Journal of Chemical and Pharmaceutical Research, 1(3), 163-177. [Google Scholar] [Crossref]

15. Harborne J. B. (1998). Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis (3rd ed.). Springer, London. [Google Scholar] [Crossref]

16. Houghton, P.J and Raman, A. (1999). Laboratory Hand book for the fractionation of Natural Extracts London, Chapman, and Hall [Google Scholar] [Crossref]

17. World Health Organization. Quality control methods for medicinal plant materials. Geneva: WHO; 1998. Available from: https://www.who.int/docs/default-source/medicines/norms-and-standards/guidelines/quality-control/quality-control-methods-for-medicinal-plant-materials.pdf [Google Scholar] [Crossref]

18. Shah, D. S., Moravkar, K. K., Jha, D. K., Lonkar, V., Amin, P. D., & Chalikwar, S. S. (2023). A concise summary of powder processing methodologies for flow enhancement. Heliyon, 9(6), e16498. [Google Scholar] [Crossref]

19. Molyneux P. (2004). The use of the stable free radical diphenyl picrylhydrazyl (DPPH) for estimating antioxidant activity. Songklanakarin Journal of Science and Technology, 26(2): 211–219. [Google Scholar] [Crossref]

20. Afieroho O.E.. and Akabuogu TA. (2020). Free radical scavenging activity of chromatography fractions of Dirinaria picta on two host trees. Singapore Journal of Scientific Research 2020; 10(1):59-64. [Google Scholar] [Crossref]

21. Batista, E. K., Lima, L. M. A., Gomes, D. A., Crans, D. C., Silva, W. E., Belian, M. F., & Lira, E. C. (2024). Dexamethasone-Induced Insulin Resistance Attenuation by Oral Sulfur-Oxidovanadium(IV) Complex Treatment in Mice. Pharmaceuticals (Basel, Switzerland), 17(6), 760. [Google Scholar] [Crossref]

22. Aleixandre-Tudo, J. L., and du Toit, W. (2018). The role of UV-visible spectroscopy for phenolic compounds quantification in winemaking. In Frontiers and new trends in the science of fermented food and beverages. IntechOpen. [Google Scholar] [Crossref]

23. Ceylan-Isik, A. F., Fliethman, R. M., Wold, L. E., & Ren, J. (2008). Herbal and traditional Chinese medicine for the treatment of cardiovascular complications in diabetes mellitus. Current diabetes reviews, 4(4), 320–328. [Google Scholar] [Crossref]

24. Li, W. L., Zheng, H. C., Bukuru, J., & De Kimpe, N. (2004). Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. Journal of ethnopharmacology, 92(1), 1–21. [Google Scholar] [Crossref]

25. Sridevi N, & Thirumal M. (2025). Evaluation of polyherbal synergy against diabetes: in-vitro analysis. Future science OA, 11(1), 2468128. [Google Scholar] [Crossref]